trending Market Intelligence /marketintelligence/en/news-insights/trending/H1ac-UbglsbLtw-WU4zzjg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Teva, BioDelivery reach settlement over opioid addiction drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva, BioDelivery reach settlement over opioid addiction drug

Teva Pharmaceutical Industries Ltd. agreed not to sell a generic version of BioDelivery Sciences International Inc.'s opioid addiction treatment as part of a settlement to end a patent litigation against the company.

Teva is barred from marketing a generic version of Bunavail until July 23, 2028.

BioDelivery filed a lawsuit in the U.S. District Court for the District of Delaware after Teva filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the drug.

BioDelivery said the abbreviated new drug application infringed on several of its patents.